InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register account icon
S&P 500
5,528.89
(
-1.06%
)
US TECH 100
19,099.36
(
-0.89%
)
Dow Jones
40,630.52
(
-1.38%
)
Brent Oil
83.96
(
-0.63%
)
Bitcoin
63,276.80
(
-1.26%
)
Post# of 252638
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 831
Posts 120078
Boards Moderated 17
Alias Born 09/05/2002

DewDiligence

Member Level

Re: DewDiligence post# 121028

Monday, 06/06/2011 3:37:42 AM

Monday, June 06, 2011 3:37:42 AM

Post# of 252638
Alimta in NSCLC is a case in point:

http://finance.yahoo.com/news/New-Study-Released-Today-prnews-1158574655.html?x=0&.v=1

…Phase III study evaluating ALIMTA in the continuation maintenance setting, met its primary endpoint of progression-free survival…for patients with…advanced nonsquamous non-small cell lung cancer (NSCLC). "Continuation maintenance" treatment is when one of the same medicines used in first-line treatment setting is continued as maintenance therapy in an effort to control the cancer.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up